Plain-English translation of NCT05946772 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Takotsubo syndrome is a rare but serious heart condition that happens suddenly, usually after severe emotional or physical stress. Your heart's pumping chamber weakens temporarily, and doctors aren't sure how to treat it yet. This trial is testing whether —a medication that calms inflammation in the heart—can help your heart recover better and faster than standard care alone.
Right now, there is no proven treatment for takotsubo syndrome, and some patients suffer serious complications or even death even though the heart often recovers on its own. Researchers discovered in animal studies that this medication may protect the heart by reducing dangerous inflammation, so they want to test whether it works safely and effectively in real patients.
You likely qualify if…
You likely don't qualify if…
You will receive three doses of either the study medication or a placebo (a dummy treatment with no active ingredient) through an IV—one at the start, one after 12 hours, and one after 24 hours. Researchers will measure heart damage, heart function, and swelling in your heart tissue over the next few days and will follow up with you at 30 days and 1 year to see how well you recover and how you're feeling.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Germany